

Fremanezumab for preventing migraine

Information for the public

Published: 2 February 2022

www.nice.org.uk

Fremanezumab (Ajovy) is available on the NHS as a possible treatment for migraine in adults if they have:

- migraines on 4 or more days a month
- tried at least 3 preventive medications already and they have not worked, or are not tolerated or are unsuitable because of safety concerns.

You should only carry on taking fremanezumab after 12 weeks of treatment if you have:

- episodic migraine (fewer than 15 headache days a month) and it has reduced by at least half (for example, from 10 days to 5 days a month)
- chronic migraine (15 headache days a month or more, and at least 8 of those have been migraines) and it has reduced by at least 30% (for example, from 20 days to 14 days a month).

If you are not eligible for fremanezumab but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Migraine Trust](#), 0808 802 0066
- [Ouch UK](#), 0800 6696 824

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4421-7